Suzuki M, Ohwada M, Aida I, Sato I, Tamada T
Department of Obstetrics and Gynecology, Jichi Medical School, Tochigi, Japan.
Gynecol Oncol. 1994 Jul;54(1):23-6. doi: 10.1006/gyno.1994.1160.
To assess the effects of macrophage colony-stimulating factor (M-CSF) on platelet recovery in patients given chemotherapy for advanced and recurrent ovarian cancer, we selected 29 cases treated with carboplatin (280 mg/m2, Day 1) and cisplatin (70 mg/m2, Day 2). We evaluated the response and the platelet recovery effects of M-CSF, which was infused intravenously for 7 consecutive days after the second and fourth courses of chemotherapy. For the 54 courses of M-CSF infusion, the platelet nadir averaged 12.8 +/- 6.3 x 10(4)/microliters, with 9% of the courses designated Grade 3 or 4 on the toxicity scale, according to World Health Organization recommendations, both of which were significantly different from the M-CSF noninfused control courses (P < 0.05). The number of periods in which platelets were below 7.5 x 10(4)/microliters was significantly less in the courses of M-CSF infusion (P < 0.01). Response to treatment was pathologic complete in 23% and partial in 41%, for a total response of 64%. Cisplatin combined with carboplatin was effective in treating patients with advanced and recurrent ovarian cancer. M-CSF infusion may enhance the recovery from the thrombocytopenia that accompanies such chemotherapy.
为评估巨噬细胞集落刺激因子（M-CSF）对晚期复发性卵巢癌化疗患者血小板恢复情况的影响，我们选取了29例接受卡铂（280mg/m²，第1天）和顺铂（70mg/m²，第2天）治疗的患者。我们评估了M-CSF的反应及血小板恢复效果，M-CSF在第二和第四疗程化疗后连续7天静脉输注。在54个M-CSF输注疗程中，血小板最低点平均为12.8±6.3×10⁴/微升，按照世界卫生组织的建议，9%的疗程在毒性量表上被判定为3级或4级，这两者均与未输注M-CSF的对照疗程有显著差异（P<0.05）。在M-CSF输注疗程中，血小板低于7.5×10⁴/微升的时间段数量显著更少（P<0.01）。治疗反应中病理完全缓解率为23%，部分缓解率为41%，总缓解率为64%。顺铂联合卡铂对晚期复发性卵巢癌患者有效。输注M-CSF可能会促进此类化疗伴随的血小板减少症的恢复。
